All In Biotech

Drug Trial Radar · NCT03194893

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

50

Actual

Start

Jul 5, 2017

Primary completion

Sep 18, 2025

Study completion Sep 18, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.

Conditions

  • Neoplasms

Interventions

  • AlectinibDrug

    Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.

  • CrizotinibDrug

    Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)Time frame: From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)

Locations

29 sites in 9 countries. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center

    Orange, California

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Centre Francois Baclesse

    Caen, France

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Oscar Lambret

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Groupe Hospitalier Sud - Hôpital Haut Lévêque

    Pessac, France

  • Hopital Pontchaillou - CHU de Rennes

    Rennes, France

  • CHU de Toulouse - Hôpital Larrey

    Toulouse, France

  • Hopital Robert Schuman

    Vantoux, France

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital Department of Clinical Oncology

    Kowloon, Hong Kong

  • Irccs Centro Di Riferimento Oncologico (CRO)

    Aviano, Friuli Venezia Giulia, Italy

  • Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1

    Rome, Lazio, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Tuscany, Italy

  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia

    Perugia, Umbria, Italy

  • Uniwersyteckie Centrum Kliniczne

    Gda?sk, Poland

  • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"

    Moscow, Moscow Oblast, Russia

  • University ?linic of headaches

    Moscow, Moscow Oblast, Russia

  • City Clinical Oncology Hospital

    Moscow, Moscow Oblast, Russia

  • Seoul National University Hospital

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital del Mar

    Barcelona, Spain

  • Hospital Universitari Dexeus - Grupo Quironsalud

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Adana Ac?badem Hospital Oncology Department

    Adana, Turkey (Türkiye)

  • Istanbul Uni Capa Medical Faculty

    Istanbul, Turkey (Türkiye)

  • Ege University Medical Faculty

    Izmir, Turkey (Türkiye)

  • Hacettepe Uni Medical Faculty Hospital

    S?hhiye, Ankara, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.